
==== Front
J Exp Clin Cancer Res
J Exp Clin Cancer Res
Journal of Experimental & Clinical Cancer Research : CR
0392-9078
1756-9966
BioMed Central London

3183
10.1186/s13046-024-03183-9
Correction
Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy
http://orcid.org/0000-0003-0068-7191
He Kewen hekewen9144@foxmail.com

12
Puebla-Osorio Nahum 2
Barsoumian Hampartsoum B. 2
Sezen Duygu 23
Rafq Zahid 2
Riad Thomas S. 2
Hu Yun 2
Huang Ailing 2
Voss Tifany A. 2
Kettlun Leyton Claudia S. 2
Schuda Lily Jae 2
Hsu Ethan 2
Heiber Joshua 4
Cortez Maria-Angelica 2
Welsh James W. jwelsh@mdanderson.org

2
1 grid.410587.f 0000 0004 6479 2668 Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong China
2 https://ror.org/04twxam07 grid.240145.6 0000 0001 2291 4776 Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA
3 https://ror.org/00jzwgz36 grid.15876.3d 0000 0001 0688 7552 Department of Radiation Oncology, Koç University School of Medicine, Istanbul, Turkey
4 Mural Oncology PLC, Waltham, MA USA
10 9 2024
10 9 2024
2024
43 256© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
issue-copyright-statement© Italian National Cancer Institute ‘Regina Elena’ 2024
==== Body
pmc Correction: J Exp Clin Cancer Res 43, 251 (2024)

10.1186/s13046-024-03165-x

Following publication of the original article [1], the authors found an error in the affiliation of the 5th author, Zahid Rafiq. He was mistakenly assign to Affiliation 1. The details are given below:

Incorrect affiliation:

1 Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.

Correct affiliation:

2 Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

This correction does not affect the overall result or conclusion of the article. The original article [1] has been corrected.

The online version of the original article can be found at 10.1186/s13046-024-03165-x.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
Reference

1. He K Puebla-Osorio N Barsoumian HB Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy J Exp Clin Cancer Res 2024 43 251 10.1186/s13046-024-03165-x 39218928
He K, Puebla-Osorio N, Barsoumian HB, et al. Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024;43:251. 10.1186/s13046-024-03165-x.39218928 10.1186/s13046-024-03165-x
